Other Consolidated Financial Statement Detail (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010	Dec. 31, 2010
Other income (expense), net
Interest income	$ 5,300,000	$ 3,100,000	$ 13,300,000	$ 18,600,000
Interest expense	(7,900,000)	(9,300,000)	(25,500,000)	(26,600,000)
Impairments of investments	(800,000)	(2,800,000)	(7,600,000)	(19,800,000)
Foreign exchange losses, net	(4,800,000)	(3,500,000)	(5,800,000)	(3,200,000)
Gain (loss) on sales of investments, net	(100,000)	4,800,000	15,400,000	16,100,000
Other, net	600,000	800,000	700,000	600,000
Total other income (expense), net	(7,727,000)	(6,945,000)	(9,504,000)	(14,318,000)
Other current assets
Deferred tax assets	38,200,000		38,200,000		112,200,000
Prepaid taxes	29,400,000		29,400,000		31,400,000
Receivable from collaborations	12,900,000		12,900,000		7,300,000
Interest receivable	7,600,000		7,600,000		4,900,000
Derivative assets	18,900,000		18,900,000		1,300,000
Other prepaid expenses	60,800,000		60,800,000		47,900,000
Other	26,400,000		26,400,000		10,800,000
Total other current assets	194,199,000		194,199,000		215,822,000
Accrued Expenses and Other
Employee compensation and benefits	144,300,000		144,300,000		159,700,000
Revenue-related rebates	119,200,000		119,200,000		105,300,000
Restructuring charges	2,600,000		2,600,000		66,400,000
Royalties and licensing fees	42,900,000		42,900,000		45,100,000
Deferred revenue	59,900,000		59,900,000		41,300,000
Collaboration expenses	51,700,000		51,700,000		31,600,000
Clinical development expenses	42,600,000		42,600,000		24,400,000
Interest payable	5,400,000		5,400,000		21,600,000
Construction in progress accrual	16,300,000		16,300,000		16,400,000
Current portion of contingent consideration	9,000,000		9,000,000		11,900,000
Derivative liabilities	2,000,000		2,000,000		12,200,000
Other	178,800,000		178,800,000		130,000,000
Total accrued expenses and other	$ 674,743,000		$ 674,743,000		$ 665,923,000